Expanding roles of BCL-2 proteins in apoptosis execution and beyond.


Journal

Journal of cell science
ISSN: 1477-9137
Titre abrégé: J Cell Sci
Pays: England
ID NLM: 0052457

Informations de publication

Date de publication:
15 Nov 2023
Historique:
medline: 27 11 2023
pubmed: 23 11 2023
entrez: 23 11 2023
Statut: ppublish

Résumé

The proteins of the BCL-2 family are known as key regulators of apoptosis, with interactions between family members determining permeabilisation of the mitochondrial outer membrane (MOM) and subsequent cell death. However, the exact mechanism through which they form the apoptotic pore responsible for MOM permeabilisation (MOMP), the structure and specific components of this pore, and what roles BCL-2 proteins play outside of directly regulating MOMP are incompletely understood. Owing to the link between apoptosis dysregulation and disease, the BCL-2 proteins are important targets for drug development. With the development and clinical use of drugs targeting BCL-2 proteins showing success in multiple haematological malignancies, enhancing the efficacy of these drugs, or indeed developing novel drugs targeting BCL-2 proteins is of great interest to treat cancer patients who have developed resistance or who suffer other disease types. Here, we review our current understanding of the molecular mechanism of MOMP, with a particular focus on recently discovered roles of BCL-2 proteins in apoptosis and beyond, and discuss what implications these functions might have in both healthy tissues and disease.

Identifiants

pubmed: 37994778
pii: 335501
doi: 10.1242/jcs.260790
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins c-bcl-2 0
bcl-2-Associated X Protein 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : CRC1218

Informations de copyright

© 2023. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interests The authors declare no competing or financial interests.

Auteurs

Louise E King (LE)

Institute for Genetics, CECAD Research Center, University of Cologne, Cologne 50931, Germany.

Lisa Hohorst (L)

Institute for Genetics, CECAD Research Center, University of Cologne, Cologne 50931, Germany.

Ana J García-Sáez (AJ)

Institute for Genetics, CECAD Research Center, University of Cologne, Cologne 50931, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH